Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Personalized infliximab therapy in severe sarcoidosis
NL-OMON39486Active, not recruiting
- Sponsor
- St. Antonius Ziekenhuis
- Start
- Jan 2011
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of infliximab in sarcoidosis, sponsored by St. Antonius Ziekenhuis. Primary endpoints: Subtherapeutic infliximab trough concentration, Anti-infliximab antibody positivity and 6 more. Started Jan 2011; status: active, not recruiting.
02
Drugs
infliximab
03
Conditions
sarcoidosis
Beyond the preview
Go deeper on NL-OMON39486.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39486.